How participants in cancer trials are chosen: Ethics and conflicting interests

Gordon Jayson, John Harris

    Research output: Contribution to journalArticlepeer-review


    The development of new drugs for cancer is extremely complex and expensive, and poses ethical problems. In this article we will review issues in clinical trials for cancer drugs that will cast new light on the doctor-patient relationship and their interaction with industry, the health service, academic and administrative organizations. We show that the Declaration of Helsinki cannot be applied to cancer trials as it is currently written, that patients do not and perhaps cannot give fully informed consent to participate, and that the results of clinical trials do not translate into daily practice in a way that patients might expect. © 2006 Nature Publishing Group.
    Original languageEnglish
    Pages (from-to)330-336
    Number of pages6
    JournalNature Reviews Cancer
    Issue number4
    Publication statusPublished - Apr 2006


    • *Clinical Trials as Topic
    • *Conflict of Interest
    • *Ethics, Medical
    • Humans
    • Neoplasms/*therapy
    • *Patient Selection


    Dive into the research topics of 'How participants in cancer trials are chosen: Ethics and conflicting interests'. Together they form a unique fingerprint.

    Cite this